We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Fragmented Red Blood Cell Measurement Automated

By LabMedica International staff writers
Posted on 02 Jul 2012
The laboratory diagnosis of thrombotic microangiopathies (TMA) or disorders that may mimic their features remains difficult.

The detection of schistocytes on the blood smear is a cornerstone finding to assess the diagnosis, but microscopic evaluation of schistocytes is still problematic with wide inter-observer variations.

Image: Schistocytes in blood smear (Photo courtesy of Dr. Paulo H.O. Mourao).
Image: Schistocytes in blood smear (Photo courtesy of Dr. Paulo H.O. Mourao).

Hematologists at the University Hospital (Nancy, France) conducted studies comparing automated and microscopic counts of Fragmented Red Blood Cells (FRC) and schistocytes. The data came from the day-to-day analysis of more than 90,000 peripheral blood (PB) samples for 10 years in four centers. More than 900 patients were examined because of a clinical suspicion of TMA and 17 samples were derived from preterm newborns who were supposed to give the highest FRC counts among nonpathologic samples.

FRC were counted by automated direct measurement using the two automated analyzers (ABCC): the ADVIA 120 analyzer (Siemens; Tarrytown, NY, USA) and the XE-2100 analyzer (Sysmex; Kobe, Japan). Schistocyte counting was carried out from May-Grünwald-Giemsa-stained PB smears. The reference range for FRC was less than 0.3% for the ADVIA and less than 0.5% for the Sysmex XE-2100.

The correlation coefficient for Siemens devices was around 0.7. The main problem resulted from an overestimation of FRC as compared to schistocytes from 0.4% to 0.5% for a count of schistocyte ranging from 0% to 1.5%. Conversely, the scientists observed an underestimation of FRC as compared to schistocytes subsequent to this 1.5% threshold. For the Sysmex XE-2100 counter, the overestimation of the FRC was more pronounced, at less 0.8%, and increased slightly with high schistocyte percentages. The presence of FRC below a threshold determined at 1% for both automated analyzers had a negative predictive value (PV) close to 100% to exclude the presence of schistocyte on the blood smear, but in relationship with a poor positive PV value.

The authors concluded that that systematic quantification of FRC might improve the laboratorians' ability to exclude samples with schistocytes. This should be especially useful among patients in whom TMA diagnosis is suspected. However, several limitations deserve consideration such as few false-negative FRC counts in a context of macrocytosis, great lack of specificity. Hence, a PB smear examination was still advised for the validation of the count if needed. The study was published on June 14, 2012, in the International Journal of Laboratory Hematology.

Related Links:

University Hospital
Siemens
Sysmex



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Latest Hematology News

New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder

Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy

WBC Count Could Predict Severity of COVID-19 Symptoms



Sekisui Diagnostics UK Ltd.